IRCT2013012612274N1已完成3 期
Evaluation of the Clinical safety and efficacy of Suprimun compared with Cellcept in renal transplant recipients
Vice-Chancellor for Research, Shahid Beheshti University of Medical Sciences0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years(—)
- 性别
- All
入选标准
- •Inclusion Criteria:
- •Have signed the informed consent form; Have a BMI (body mass index) between 18.5 and 24.9; Are male or females between the age of 18 and 60years old; Are going to be transplanted (kidney) for the first time; Are willing to begin and continue treatment with the triple scheme (corticosteroids, cyclosporine and Suprimun/Cellcept®); Are going to benefit from this triple scheme; Are in good general medical conditions; Agree to use birth control methods; Have ABO compatibility; Have low immunologic risk (PRA < 20%, high HLA compatibility); Are taking MMF with a total dose of 2 gr/d (4 tablets); Are receiving transplant from non-relative and alive donors.
- •Exclusion Criteria :
- •Receive Mycophenolate Mofetil from another brandname; Have active Hepatitis B or C; Is intolerant to any of the drugs of the triple scheme; Have any medical condition that can interfere with the normal follow up of the study; Has a history of MI, life-threatening arrhythmia or CVA in the last 6 month , history of malignancy, pregnancy and breastfeeding; Have participated in another clinical study 3 months ago or less before the selection visit; Any induction Therapy (ATG , IL2 receptor inhibitor) before or during the surgery; Any renal rejection with non-relative reason to Mycophenolate drug during 48h after the surgery.(Vascular rejection, urological rejection); Taking medications that interfere with the action of the drug, including: Magnesium and Aluminum Hydroxide, Cholestyramine, phenytoin , diltiazem and Probenecid, any live vaccines; Are being transplanted for 2nd or 3rd time, or from cadaver; Be addicted to alcohol or illegal drugs;Be HIV positive
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Evaluation of the Clinical Safety and Efficacy of Suprimun in Renal Transplant RecipientsComparative Interventional Treatment for reduceing the renal transplant rejection.kidney transplant rejectionIRCT2014072118548N1Research Deputy of Kermanshah University Of Medical Sciences60
进行中(未招募)
1 期
A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril,indapamide and amlodipine in patients with essential hypertension whose blood pressure remains high on perindopril, indapamide and amlodipine treatment.MedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersHypertensionEUCTR2020-004891-16-LVInstitut de Recherches Internationales Servier968
招募中
不适用
Evaluation of the clinical efficacy and safety of fluticasone propionate/ formoterol fumarate combination (FFC) for the treatment of bronchial asthma-with and without use of an inhalation deviceBronchial AsthmaJPRN-UMIN000015602Kinki university Department of respiratory medicine and allergology50
进行中(未招募)
1 期
A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril,indapamide and amlodipine in patients with essential hypertension whose blood pressure remains high on perindopril, indapamide and amlodipine treatment.MedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersHypertensionEUCTR2020-004891-16-CZInstitut de Recherches Internationales Servier968
进行中(未招募)
1 期
A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril,indapamide and amlodipine in patients with essential hypertension whose blood pressure remains high on perindopril, indapamide and amlodipine treatment.MedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersHypertensionEUCTR2020-004891-16-PLInstitut de Recherches Internationales Servier968
